HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Supplement Firm Turns Attention To Ingredient Supply After NAD Review

Executive Summary

Vaya marketed Vayarin supplement in the US, but its parent firm, specialty chemicals company Enzymotec, responds to NAD request for substantiation by saying that it changed "its strategy to focus on serving as an ingredient-supplier rather than engaging in the sale of consumer products." Change includes closing Vaya and ceasing Vayarin sales in the US.

Advertisement

Related Content

'Enhanced Brain Function' Supplement Sales Only A Memory After NAD Review

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS148820

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel